Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3772847 in moderate to severe asthma with allergic fungal airway disease
NL-OMON46085Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma and allergic bronchopulmonary mycosis (ABPM) comparing GSK3772847 + standard of care with Placebo + standard of care (2 arms). Primary endpoints: Change from baseline in blood eosinophils over time and Change from baseline in fractional exhaled nitric oxide over time. Started Oct 2018; status: completed.
02
Drugs
melrilimab
03
Conditions
asthmaallergic bronchopulmonary mycosis (ABPM)
Beyond the preview
Go deeper on NL-OMON46085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46085.